Last Updated: November 18, 2026

MONOBASIC SODIUM PHOSPHATE AND DIBASIC SODIUM PHOSPHATE Drug Patent Profile

« Back to Dashboard


Which patents cover Monobasic Sodium Phosphate And Dibasic Sodium Phosphate, and when can generic versions of Monobasic Sodium Phosphate And Dibasic Sodium Phosphate launch?

Monobasic Sodium Phosphate And Dibasic Sodium Phosphate is a drug marketed by Novel Labs Inc and is included in one NDA.

The generic ingredient in MONOBASIC SODIUM PHOSPHATE AND DIBASIC SODIUM PHOSPHATE is sodium phosphate, dibasic, anhydrous; sodium phosphate, monobasic, monohydrate. There is one drug master file entry for this compound. Additional details are available on the sodium phosphate, dibasic, anhydrous; sodium phosphate, monobasic, monohydrate profile page.

AI Deep Research
Questions you can ask:
  • What is the 5 year forecast for MONOBASIC SODIUM PHOSPHATE AND DIBASIC SODIUM PHOSPHATE?
  • What are the global sales for MONOBASIC SODIUM PHOSPHATE AND DIBASIC SODIUM PHOSPHATE?
  • What is Average Wholesale Price for MONOBASIC SODIUM PHOSPHATE AND DIBASIC SODIUM PHOSPHATE?
Summary for MONOBASIC SODIUM PHOSPHATE AND DIBASIC SODIUM PHOSPHATE
US Patents:0
Applicants:1
NDAs:1
DailyMed Link:MONOBASIC SODIUM PHOSPHATE AND DIBASIC SODIUM PHOSPHATE at DailyMed
Pharmacology for MONOBASIC SODIUM PHOSPHATE AND DIBASIC SODIUM PHOSPHATE

US Patents and Regulatory Information for MONOBASIC SODIUM PHOSPHATE AND DIBASIC SODIUM PHOSPHATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novel Labs Inc MONOBASIC SODIUM PHOSPHATE AND DIBASIC SODIUM PHOSPHATE sodium phosphate, dibasic, anhydrous; sodium phosphate, monobasic, monohydrate TABLET;ORAL 079247-001 Dec 30, 2011 RX No Yes ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Monobasic Sodium Phosphate and Dibasic Sodium Phosphate Market Dynamics and Financial Trajectory

Last updated: October 4, 2026

The monobasic sodium phosphate and dibasic sodium phosphate market is a mature, low-cost pharmaceutical segment dominated by sodium phosphate enemas and legacy oral bowel-cleansing products. The principal commercial opportunity is the over-the-counter rectal laxative category, led by Fleet products from Prestige Consumer Healthcare. Revenue is supported by recurring constipation treatment and procedure-preparation demand, but long-term growth is constrained by low pricing, generic competition, polyethylene glycol substitution, renal-safety warnings, and limited product differentiation.

Brand-level revenue is not publicly disclosed. Prestige reports Fleet within broader OTC health-care results, so the financial trajectory must be assessed through category demand, brand ownership, regulatory exposure, and competitive substitution rather than a standalone income statement.

What are monobasic sodium phosphate and dibasic sodium phosphate products used for?

Sodium phosphate monobasic and sodium phosphate dibasic are saline laxative ingredients used primarily for:

  • Rectal enemas for occasional constipation
  • Bowel evacuation before diagnostic procedures
  • Historical oral tablet or solution bowel-preparation products
  • Hospital and institutional bowel-management protocols

The leading commercial presentation is the single-use sodium phosphate enema. A typical 118-milliliter adult product contains approximately 19 grams of monobasic sodium phosphate and 7 grams of dibasic sodium phosphate, although strengths and hydration states vary by manufacturer and dosage form.[1]

The ingredients work by drawing water into the bowel and stimulating evacuation. Their low manufacturing cost and rapid onset support continued use in retail pharmacies, mass merchants, hospitals, and ambulatory surgery centers.

What dosage forms are commercially important?

Dosage form Primary use Commercial status Market outlook
Rectal enema Occasional constipation and bowel evacuation Active OTC category Stable, price-sensitive
Oral solution Bowel preparation Limited and safety-constrained Vulnerable to substitution
Oral tablets Colonoscopy preparation Legacy or restricted products Declining relative importance
Institutional formulations Hospital bowel management Contract and formulary driven Small, fragmented

The enema category is commercially stronger than oral sodium phosphate bowel preparation because rectal administration generally produces lower systemic exposure than large-dose oral regimens. Oral phosphate products have faced serious safety concerns involving acute phosphate nephropathy, electrolyte disturbances, dehydration, and renal injury.[2]

How large is the sodium phosphate laxative market?

No public source isolates global revenue for monobasic sodium phosphate and dibasic sodium phosphate as active pharmaceutical ingredients. Market estimates generally combine multiple saline laxatives, dosage forms, geographies, and branded and private-label products.

The commercially relevant market is fragmented across:

  • Branded Fleet enemas
  • Store-brand and pharmacy-brand sodium phosphate enemas
  • Hospital and institutional suppliers
  • Regional generic manufacturers
  • Competing non-phosphate laxatives
  • Bowel-preparation products based on polyethylene glycol, sulfate salts, magnesium salts, or stimulant combinations

The economic structure is typical of a mature OTC medicine. Unit manufacturing costs are low, shelf space and distribution are important, and brand recognition can preserve a retail price premium despite generic availability.

Which companies compete in sodium phosphate enemas?

Competition includes Prestige Consumer Healthcare through the Fleet brand, private-label retailers, contract manufacturers, and regional generic suppliers. Retailers may source comparable enemas under pharmacy, supermarket, mass-market, and e-commerce labels.

The market does not have the concentration or pricing power associated with patented prescription medicines. Competitive advantages are more likely to come from:

  • Retail distribution
  • Brand recognition
  • Reliable supply
  • Packaging and applicator design
  • Pediatric and adult line extensions
  • Private-label manufacturing relationships
  • Regulatory compliance and quality systems

Who owns the leading sodium phosphate enema brand?

Prestige Consumer Healthcare owns the Fleet brand portfolio. Fleet is included in Prestige’s broader North American over-the-counter health-care business, which also includes products such as Clear Eyes, Dramamine, Monistat, Summer’s Eve, Debrox, Chloraseptic, and BC/Goody.[3]

Prestige does not separately report Fleet net sales, gross margin, operating income, or cash flow. This prevents a precise calculation of:

  • Fleet annual revenue
  • Sodium phosphate product revenue
  • Fleet market share
  • Product-level EBITDA
  • Revenue contribution from enemas versus other Fleet products

The lack of separate disclosure indicates that investors should treat Fleet as one component of a diversified OTC portfolio rather than as a separately valued pharmaceutical asset.

What is the financial trajectory for Fleet and similar sodium phosphate products?

The likely trajectory is stable to modestly declining in real terms, with periodic nominal growth from price increases, distribution gains, or retail mix.

Financial driver Direction Effect
Recurring constipation demand Stable Supports baseline volume
Aging population Positive Increases constipation-treatment demand
Low-cost generic supply Negative Limits pricing power
Retail private-label competition Negative Compresses unit economics
E-commerce availability Mixed Expands access but increases price transparency
Colonoscopy volumes Positive but variable Supports bowel-preparation demand
PEG and sulfate substitution Negative Reduces phosphate use in procedure preparation
Renal-safety concerns Negative Restricts oral and high-dose use
OTC price inflation Positive nominally May mask flat or falling unit volume

Prestige’s acquisition-led model can improve reported revenue through price realization, distribution, and portfolio management, but those factors do not necessarily indicate volume expansion for sodium phosphate products. A mature saline laxative generally has limited innovation-led growth.

What is the FDA regulatory status of sodium phosphate products?

Rectal sodium phosphate laxatives are regulated as over-the-counter products under the FDA’s laxative framework. The FDA-approved labeling for sodium phosphate enemas contains age restrictions, dosing limits, contraindications, and warnings related to dehydration, kidney disease, heart disease, bowel obstruction, abdominal pain, and excessive use.[1]

Important labeling controls include:

  • Do not use more than one enema in 24 hours unless directed by a physician
  • Do not use in young children without medical direction
  • Avoid use in patients with kidney disease, heart disease, dehydration, or electrolyte abnormalities
  • Seek medical advice when constipation persists or symptoms suggest obstruction
  • Stop use and obtain medical attention for rectal bleeding or lack of bowel movement after use

The FDA has warned that oral sodium phosphate products can cause serious kidney injury and severe electrolyte abnormalities. Risk is higher in older adults, patients with renal impairment, patients taking diuretics or renin-angiotensin system medicines, and patients who become dehydrated.[2]

What is the Orange Book status of Fleet sodium phosphate enemas?

Fleet OTC enemas are generally marketed under the FDA’s OTC drug framework rather than through a conventional prescription NDA with an Orange Book patent listing. As a result:

  • There is no standard Orange Book exclusivity period for the OTC monograph product.
  • There is no conventional Paragraph IV pathway directed at the Fleet OTC enema itself.
  • Generic and private-label competition can enter through the applicable OTC regulatory route.
  • Product-specific prescription sodium phosphate tablets or solutions may have separate historical NDA and Orange Book records.

The absence of Orange Book protection does not eliminate commercial barriers. Manufacturing compliance, product quality, packaging, supply reliability, retailer access, and trademark rights remain relevant.

What patents protect monobasic sodium phosphate and dibasic sodium phosphate products?

The active ingredients are old, well-known inorganic salts and are not protected by meaningful composition-of-matter patents. Any enforceable intellectual-property value is more likely to arise from:

  • Applicator design
  • Container geometry
  • Child-resistant or tamper-evident packaging
  • Manufacturing methods
  • Stability or fill-volume controls
  • Combination products
  • Proprietary bowel-preparation formulations
  • Trademarks and trade dress

For a standard sodium phosphate enema, patent risk is materially lower than regulatory and commercial execution risk. A competitor can generally develop a comparable product without needing a license to the active ingredients.

How strong is the patent estate?

The patent estate is weak at the active-ingredient level and potentially moderate at the product or device level. The distinction matters:

IP category Strength for standard sodium phosphate enema
Active ingredient Very weak; legacy salts
Basic laxative use Very weak
Standard formulation Weak
Applicator or container Potentially narrow
Trade dress and brand Commercially meaningful
Manufacturing know-how Potentially useful but difficult to assess publicly
Oral bowel-prep combinations Product-specific and variable

Patent expiration is therefore less important than regulatory pathway and supply-chain readiness. Public patent records should be reviewed by product, assignee, jurisdiction, and claim scope before making a launch or licensing decision.

Are there Paragraph IV challenges or patent litigation?

There is no central, high-value Paragraph IV litigation pattern associated with standard OTC sodium phosphate enemas. The product class is mature, and market entry generally does not depend on challenging a remaining patent protecting the active ingredients.

Potential disputes are more likely to involve:

  • Trademark infringement
  • Trade dress
  • Product labeling
  • Advertising claims
  • Manufacturing quality
  • Product liability
  • Retail or supply contracts
  • Device or applicator design

Historical litigation involving oral sodium phosphate bowel preparations has been more closely tied to safety allegations and product liability than to durable patent monopolies. The financial significance of litigation depends on whether a claim targets a major branded product, a manufacturing site, or a broad class of users.

What generic launch scenarios exist?

Scenario 1: Continued branded OTC competition

Fleet retains shelf presence and brand recognition while private-label products compete on price. This scenario supports stable revenue but limits margin expansion.

Scenario 2: Private-label volume migration

Retailers increase store-brand sourcing. Unit volume remains intact, but branded share and net pricing decline.

Scenario 3: Procedure-preparation substitution

Hospitals and gastroenterology practices shift from phosphate-based products toward polyethylene glycol or sulfate-based preparations. This scenario affects oral products more severely than enemas.

Scenario 4: Safety-driven restriction

New labeling actions or professional guidance further restrict oral phosphate use in older adults and patients with kidney disease. Rectal products could also face narrower use recommendations, although the commercial impact would likely be lower than for high-dose oral products.

Scenario 5: Supply disruption

Because the active ingredients are inexpensive but finished-dose manufacturing is specialized, a plant outage, quality recall, or packaging shortage could temporarily increase share for alternative suppliers.

How does sodium phosphate compare with polyethylene glycol bowel preparations?

Attribute Sodium phosphate Polyethylene glycol
Onset Rapid Variable
Required fluid volume Low for many enema products Often higher for oral preparation
Renal and electrolyte risk Material, especially orally Generally more favorable when appropriately used
Unit cost Low Low to moderate
Retail brand strength Fleet is prominent Highly fragmented
Procedure-prep use Declining relative role Broad and established
Patent exposure Low Product-specific
Main commercial risk Safety and substitution Competition and formulation parity

Clinicians and institutions often select bowel-preparation products based on patient comorbidities, tolerability, procedure protocols, and renal risk rather than acquisition price alone.[2]

What geographic markets offer growth?

The United States is the clearest branded market because Fleet has established retail distribution and broad consumer awareness. Canada, Europe, and other markets have different OTC classifications, product names, labeling requirements, and pharmacy-channel structures.

International growth is constrained by:

  • Country-specific registration
  • Local pharmacovigilance requirements
  • Different standards for rectal products
  • Established domestic generic suppliers
  • Varied use of enemas versus oral laxatives
  • Reimbursement and pharmacy-channel differences

The strongest opportunity is usually not a new chemical entity. It is localized registration, private-label supply, hospital contracting, or channel expansion.

What manufacturing and IP barriers affect entry?

Manufacturing barriers are operational rather than scientific. A new supplier must control:

  • Assay and impurity specifications
  • Osmolality and fill volume
  • Microbial quality
  • Container-closure integrity
  • Applicator safety
  • Stability through shelf life
  • Tamper evidence and packaging
  • FDA current good manufacturing practice compliance

The active salts are readily available commodities. Finished-product quality, regulatory documentation, and reliable supply are more important than access to proprietary chemistry.

Key Takeaways

  • Monobasic sodium phosphate and dibasic sodium phosphate are mature saline laxative ingredients.
  • The leading commercial segment is the OTC single-use enema market.
  • Prestige Consumer Healthcare owns the Fleet brand but does not disclose Fleet-specific revenue.
  • The financial trajectory is likely stable to modestly declining in unit terms, with nominal support from pricing and distribution.
  • Oral sodium phosphate bowel preparations face greater safety and substitution risk than rectal enemas.
  • Standard products have little active-ingredient patent protection and limited Paragraph IV exposure.
  • Retail distribution, private-label competition, quality systems, and supply reliability determine commercial performance.
  • Polyethylene glycol and sulfate-based bowel preparations are the main competitive alternatives in procedure preparation.
  • Regulatory and product-liability exposure is more important than patent expiration for most standard sodium phosphate products.

FAQs

Is sodium phosphate enema still commercially viable?

Yes. The category remains viable because of low manufacturing cost, rapid action, recurring constipation demand, and established retail distribution. Growth is limited by generic competition and safety-driven substitution.

Does Fleet have a patent monopoly?

No. Fleet does not have a meaningful monopoly over the active ingredients. Commercial protection comes mainly from brand recognition, distribution, packaging, manufacturing capability, and retailer relationships.

Is oral sodium phosphate safer than polyethylene glycol?

Oral sodium phosphate has a greater risk of dehydration, electrolyte abnormalities, and kidney injury in susceptible patients. Polyethylene glycol is widely used as an alternative, subject to patient-specific clinical judgment and product labeling.[2]

Can a private-label retailer launch a sodium phosphate enema?

A private-label supplier can market a comparable product if it satisfies the applicable FDA regulatory, manufacturing, labeling, packaging, and quality requirements. The principal barriers are compliance and supply execution rather than active-ingredient patents.

Does sodium phosphate revenue provide material exposure to Prestige Consumer Healthcare?

Prestige includes Fleet within a diversified OTC portfolio and does not separately report Fleet sales. Sodium phosphate products are unlikely to be valued as a standalone pharmaceutical franchise without additional company disclosure.

References

  1. U.S. Food and Drug Administration. (n.d.). DailyMed: Fleet enema, sodium phosphate monobasic and sodium phosphate dibasic labeling. National Library of Medicine.

  2. U.S. Food and Drug Administration. (2014). FDA drug safety communication: FDA warns of possible harm from exceeding recommended dose of over-the-counter sodium phosphate products to treat constipation. https://www.fda.gov

  3. Prestige Consumer Healthcare Inc. (2024). Annual report on Form 10-K for the fiscal year ended March 31, 2024. U.S. Securities and Exchange Commission.

  4. U.S. Food and Drug Administration. (n.d.). Over-the-counter monograph system and laxative drug products. https://www.fda.gov

  5. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.